...against non-catalytic, non-allosteric sites.Exo Therapeutic Inc., which is backed by Newpath Partners, Novartis Venture Fund, CRV...
...focus: Inflammation, cancerClinical status: PreclinicalFounded: 2018 by David Liu, Alan Saghatelian, Juan Pablo Maianti, Newpath, CRV...
...DimensionsUniversity collaborators: N/ACorporate partners: N/ANumber of employees: 9Funds raised: $25 millionInvestors: Newpath, Novartis Venture Fund, CRV...

...seed funding co-led by Polaris Partners and CRV...

...Ventures and Catalio Capital Management. Also participating were LS Polaris Innovation Fund, Arch Venture Partners, CRV...
...Leaf Venture Partners, Waterman Ventures, Catalio Capital Management, LS Polaris Innovation Fund, Arch Venture Partners, CRV...

...in gene therapy.” The company has raised a lone seed round from Polaris Partners and CRV...
...AG, Sarepta Therapeutics Inc. Number of employees: 20 Funds raised: $9 million Investors: Polaris Partners, CRV...

...Two Sigma Ventures, Obvious Ventures, Felicis Ventures, Epic Ventures, Menlo Ventures, AME Cloud Ventures and CRV...

...Biosciences Inc. (San Francisco, Calif.) raised $25 million in a series A round co-led by CRV...
...University of California San Francisco assistant professor Saul Kato co-founded System1. Escola serves as CEO. CRV's...

...Epic Ventures, AME Cloud Ventures, Advantage Capital and Felicix, and new investors Mubadala, Menlo Ventures, CRV...

...Epic Ventures, AME Cloud Ventures, Advantage Capital and Felicix, and new investors Mubadala, Menlo Ventures, CRV...